Introduction
Introduction
In 2009, China’s government announced plans to invest RMB1.13 trillion (0 billion) in expanding and improving healthcare provision, through significant healthcare reforms. These reforms have five key areas of focus:
This massive spending program is rapidly expanding healthcare access for China’s 1.3 billion citizens, and has implications for the pharmaceutical industry worldwide.
Scope
Report Overview
Inside China’s Healthcare Reforms: Opportunities for Multinational Pharma
This comprehensive report goes deep inside China to reveal the ways that recent reforms are changing healthcare for rural and urban citizens.Numerous local experts have been consulted for their insights, including industry experts, government officials, ministry advisers, and formulary managers.
The reader-friendly report explores each key aspect of healthcare reform in turn, clearly explaining what it is, why it was needed, and what progress has been made so far, and then summarising its specific implications for the Pharma industry. As well as covering recent reforms, the report also examines key reform priorities through to 2015.
In addition to a thorough review of reforms and their implications for Pharma, the report provides important insights and tips for building effective relationships with Chinese stakeholders.
Inside China’s Healthcare Reforms: Opportunities for Multinational Pharma is a must-have report for anyone with responsibilities or interests in China’s healthcare market.
Highlights
Key Report Features
Puchase Reasons
Who Should Read This Report?
Managers and Executives focused on global business:
Managers and Executives focused on global business:
Key Questions Answered
Key Benefits
Key quotes
“In terms of the aim to achieve universal [health insurance] coverage, this is already 95%, but the basic benefit package is still quite low. Over the next five years the reimbursement ratio will be increased for the three public insurance programmes for those patients admitted to hospital.” – Professor Hu Shanlian of Fudan University (Shanghai), an advisor to the Ministry of Health
“The implementation of universal healthcare has greatly improved the ability of the public to use medical services. Generally speaking, this is conducive to the growth performance of pharmaceutical companies.” – Dong Chaohui, vice director, Division of Health Insurance, National Institute for Social Security, MOHRSS
“Once the product is licensed and is on sale in China we try to get onto a provincial list. So you start with one province like Beijing or Shanghai... Once you successfully register the product in one provincial list, you move onto another.” – Wai Lun Ng, former CFO, AstraZeneca China
Expert Views
Table of Contents
for Inside China’s Healthcare Reforms: Opportunities for Multinational Pharma
1. Executive summary
2.Introduction
3. Key features of healthcare reform in China
3.1. Expansion of insurance coverage
3.2. Progress so far
3.3. Implications for the pharmaceutical industry
3.4. Establishment of the national essential drug list
3.5. Progress so far
3.6. Implications for the pharmaceutical industry
3.7. Revision of the national reimbursement drug list
3.8. Implications for the pharmaceutical industry
3.9. Investment in improved medical infrastructure
3.10. Progress so far
3.11. Implications for the pharmaceutical industry
3.12. Hospital finance reforms
3.13. Progress so far
3.14. Implications for the pharmaceutical industry
3.15. Consolidation of the domestic pharmaceutical industry
3.16. Consolidation of the pharmaceutical distribution industry
3.17. Engaging with distributors
4.Future reform priorities 2011-2015
4.1. Liberalization of the medical services market
4.2 Catastrophic illness coverage
4.3. Expansion of zero mark-up
5.Exploiting the reform opportunity
5.1. Drug registration process in China
5.2. Market access
5.3. One hospital at a time
5.4. Formulary inclusion
5.5. One province at a time
5.6. Soft skills
5.7. The tendering process
5.8.Structuring market access teams
5.9. Conclusions
6.Conclusions and recommendations
7.Acknowledgements
Additional Details
Publisher
FirstWord Pharma
Publisher Information
Reference
17 |
Number of Pages
68
Report Format
Related Reports
This report is published by FirstWord Pharma
Download Free Report Summary PDF
Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.
Ordering Information
Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.
Accepted Card Types
Buy now using our secure payment system.